The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc. (NASDAQ:IBRX) confirmed the US Food and Drug Administration accepted for review the supplemental Biologics License Application (sBLA)  for ANKTIVA  Plus BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer.

The supplemental BLA was accepted for review based on additional scientific data that the company provided to the FDA. The data detailed overlapping features of papillary and CIS disease that pave the way for the expansion of the already approved indication of ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with papillary tumors.

At the International Society for Pharmacoeconomics and Outcomes Research 2026 conference, Immunitybio detailed the cost savings of ANTKIVA  in the treatment of non-muscle-invasive bladder cancer patients with carcinoma in situ. ANKTIVA plus BCG showed cost savings per cystectomy of $109,622 at Year 1, $151,438 at Year 2, and $60,393 at Year 3 compared to TAR-200. The cost savings resulted from lower drug acquisition and administration costs.

ImmunityBio Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company developing next-generation immunotherapies and cell therapies that activate a patient’s immune system to fight cancer and infectious diseases. Their goal is to stimulate both innate and adaptive immune systems to generate long-lasting immunological memory.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.